Category — Pharmaceuticals

India’s Ipca Labs Acquires U.S.-based Pisgah Labs

Mumbai-based Ipca Laboratories announced the acquisition of a 100 percent share capital of Pisgah Labs Inc., a North Carolina corporation, by the company’s wholly owned subsidiary Ipca Pharmaceutical Inc., U.S.A., and Onyx Scientific Ltd., U.K. (Ipca Labs’ wholly-owned step-down subsidiary) for $9.65 million, free of debt.

Since its incorporation in 1981, Pisgah has been a contract manufacturer and developer of active pharmaceutical ingredients and intermediates. For the financial year ended April 30, 2017, Pisgah Labs accrued a total income of $2.89 million and EBIDTA of $1.14 million.

Medication

“Onyx and Pisgah’s capabilities in chemistry services will dovetail effectively with the company’s capabilities in supporting Phase II to commercial scale programs and also enable the company to manufacture small volume active pharmaceutical ingredients for the U.S. market,” a company statement said.

January 21, 2018   No Comments

India a Top 10 Trade Partner for USA

India is currently U.S.’s 9th largest goods trading partner with $67.7 billion in total (two way) goods trade during 2016. Goods exports totaled $21.7 billion; goods imports totaled $46.0 billion. The U.S. goods trade deficit with India was $24.3 billion in 2016.

According to the U.S. Census Bureau, the country’s top imports include jewelry, silverware, sporting and athletic goods, toys, basic chemicals, pharmaceuticals, medicines, apparel, accessories, textiles, and coal and petroleum products.

U.S. top exports include precious stones, pearls, metals, basic chemicals, medical and surgical equipment, metal manufacturing, computers, electronic products, and machinery other than electrical.

The tables below compare the figures for the first five months of U.S. – India trade for 2016 and 2017. The table also lists the trade figures for the first five months of 2009 which show that the trade deficit in that year was less that in recent years.  All figures below are in millions of U.S. dollars on a nominal basis and not seasonally adjusted.

Month, Year Exports Imports Month, Year Exports Imports
Jan ’17    1,703.0     3,791.9 Jan ’09

 

1,139.8 1,833.5
Jan ’16    1,485.7     3,693.3
Feb ’17    1,937.8      3,474.3 Feb ’09    1,046.8  1,579.0
Feb ’16    1,526.3      3,660.9
Mar ’17     2,114.5        4,143.9 Mar ’09    1,123.5  1,773.0
Mar ’16     1,834.5        3,997.0
Apr ’17     1,939.4        3,730.5 Apr ’09     1,268.8          1,799.2
Apr ’16     1,772.7        3,678.3
May ’17      2,056.9        4,531.1 May ’09     1,507.5  1,580.8
May ’16      1,585.9        4,124.9

Comparison of U.S. trade in goods with India for Jan to May in 2017 and 2016, and 2009.

 

August 4, 2017   No Comments

India’s Aurobindo Pharma to Expand New Jersey Facility

At its current New Jersey facility,  the company makes non-penicillin and non-cephalosporin products. The bulk of its U.S. supply comes from India, where it has six plants. It gets more than half its total revenue from selling drugs for HIV/AIDS, asthma, and schizophrenia, among others, to the U.S.

India’s drug industry is worth about $15 billion and it supplies roughly 30 percent of the medicines sold in the U.S. reports Business Line.

June 11, 2017   No Comments

Jubilant Pharma Expected to Buy American Pharma Company

Noida, India-based Jubilant Life Sciences‘ subsidiary Jubilant Pharma will negotiate a potential acquisition of a specialty business in the U.S., subject to due diligence, satisfactory agreements, and final approval of Jubilant Life Sciences.

A vial of medicine for injection

 

BusinessLine reports on a company filing at the Bombay Stock Exchange that says, “the proposed acquisition is a niche, profitable specialty pharma business with a strategic fit and is expected to provide a competitive edge for Jubilant Life Sciences’ existing business, if it materializes.”

June 11, 2017   No Comments

India Launches National Pharma Mission

The Government of India launched the National Pharma Mission for the development of bio pharmaceuticals through industry-academia collaboration. This program will focus on the development of specific products such as vaccines, biotherapeutics, and newer platform technologies for medical devices and diagnostics.

Funded by India’s central government and through a loan from the World Bank, the Mission will be implemented by the Biotechnology Industry Research Assistance Council (BIRAC), a unit of the  Department of Biotechnology. Renu Swarup, managing director of BIRAC said, “This mission is not for new discovery, but for creating infrastructure to move important early leads, which are in different stages, through the pipeline, and create products.”

Research

The National Biotechnology Development Strategy 2015-2020 announced by the Department of Biotechnology lays emphasis on making India ready to meet the challenge of achieving a $100 billion biotech industry by 2025, reports the Indian Express.

June 8, 2017   No Comments